Stay updated with breaking news from Evans Dellon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active
The ulcerative colitis drug etrasimod appeared to be efficacious in eosinophilic esophagitis, with notable reductions seen in eosinophils.
As a science writer, I’ve spent years covering the rise of allergic conditions. Why couldn’t I figure out my own?
Healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Dupilumab became the first approved treatment for eosinophilic esophagitis in 2022.